ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

BDRX Biodexa Pharmaceuticals PLC

1.09
0.10 (10.10%)
21 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Biodexa Pharmaceuticals PLC BDRX NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.10 10.10% 1.09 18:47:26
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.97 0.97 1.15 1.06 0.99
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
13/6/202408:35GLOBEResults of Annual General Meeting
10/6/202407:30GLOBETwelve month Phase 2 Clinical Trial Results of eRapa™ in..
22/5/202407:30GLOBEBiodexa Announces $7 Million of Gross Proceeds from Warrant..
21/5/202407:30GLOBEPositive Statistically Significant Phase 2 Clinical Trial..
15/5/202402:57GLOBEPosting of Annual Report & Notice of AGM - Total Voting..
30/4/202410:51GLOBEBiodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial..
26/4/202407:30GLOBEBiodexa Enters Into Exclusive License to eRapa™, a Phase 3..
19/4/202407:00GLOBEPreliminary Results for the Year Ended 31 December 2023
23/2/202407:30GLOBEBiodexa Announces Positive Top Line Phase I Clinical Trial..
13/2/202407:15APSBiotech Shares Bid Up Premarket Following 9.9% Institutional..
08/2/202407:30GLOBEBiodexa Reports 12 Month Survival in MAGIC-G1 Study of..
07/2/202407:30GLOBEBiodexa Announces Allowance of U.S. Patent Covering..
22/1/202407:30GLOBEBiodexa CEO Issues Shareholder Letter Highlighting Progress..
29/12/202303:05GLOBEBiodexa Appoints Ann Merchant to the Board of Directors
21/12/202315:00GLOBEBiodexa Announces Closing Of $6.0 Million Underwritten..
19/12/202307:42GLOBEBiodexa Announces Pricing of $5.2 Million Underwritten..
27/11/202308:00GLOBEBiodexa Enters Into Agreements to Acquire Exclusive..
03/10/202307:30GLOBEBiodexa Completes Recruitment of Cohort A in Study of MTX110..
29/9/202315:30GLOBEInterim results for the six months ended 30 June 2023
21/9/202307:30GLOBEBiodexa to Present Recruitment and Treatment Update in ..
28/7/202307:00GLOBEBiodexa Pharmaceuticals Launches New Corporate and Clinical..
24/7/202306:30GLOBEBiodexa Regain Compliance with NASDAQ Minimum Bid Price..
10/7/202307:00GLOBECompletion of Enrolment and Treatment in the Phase 1 Study..
06/7/202315:30GLOBEResults of Appeal of Delisting Determination
06/7/202307:15GLOBEPublication of Manuscript from the PNOC015 (a.k.a. MTD-201)..

Su Consulta Reciente